Complement gene expression in 4 patients with TA-TMA at time of clinical diagnosis. This figure illustrates gene expression in alternative, classical, and lectin complement pathways among cases with TA-TMA at the time of clinical diagnosis but before initiation of complement-blocking therapy with eculizumab. Red, orange, and yellow colors indicate upregulated pathways and the degree of upregulation (red > orange > yellow). Blue colors indicate downregulated and the degree of downregulation (dark blue > light blue). Red letters and red outlines indicate statistically significant changes in gene expression from pretransplant baseline to the time of TA-TMA clinical diagnosis.